My best judgment is that NWBOD will give up some of its huge price surge in coming days. I suspect that some investors won't be able to avoid the temptation to take profits. However, as I have pointed out, even with this run-up in stock price NWBOD appears to be reasonably or attractively priced in relation to its peers. I intend to ride through whatever downside may occur as opposed to trying to trade out and back in.

insider schreef:de klim is terug ingezet !

Maarten schreef:Omdat het een pink sheet is, je moet daarvoor een formulier ondertekenen dat je de risico's kent. Pink sheets = hoger risico.
En euhm glennl, ik denk dat je als beginner best wegblijft van de pink sheets.

But remember Amgen. BioVex was worth $1B to them. So far DCVax has only cost $288M, and DCVax-L is in phase III as we speak. DCVax-L and DCVax-Direct are basically the same thing, so any good news coming out DCVax-L's phase III trials will have good implications for DCVax-Direct's upcoming trials. This may just catch the attention of a big fish with the resources to pull NW Bio out of its debt hole. Somehow I don't think this company is going anywhere until we find out what DCVax-Direct can really do.